[HTML][HTML] Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate
New England Journal of Medicine, 2008•Mass Medical Soc
Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma Lysate | NEJM
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn
Prepare to become a physician, build your knowledge, lead a health care organization, and
advance your career with NEJM Group information and services. NEJM Evidence NEW! A
digital journal for innovative original research and fresh, bold ideas in clinical trial design and
clinical decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth …
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn
Prepare to become a physician, build your knowledge, lead a health care organization, and
advance your career with NEJM Group information and services. NEJM Evidence NEW! A
digital journal for innovative original research and fresh, bold ideas in clinical trial design and
clinical decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth …
In a phase 1 trial, a CMV-specific CD8+ T-cell response was induced in a patient with glioblastoma after vaccination with dendritic cells and autologous tumor. CMV in glial cells could serve as an immunotherapeutic target in glioblastoma.
The New England Journal Of Medicine